EODData

MEMBERSHIP REGISTER LOG IN

FRA, SZD: Santen Pharmaceutical Co. Ltd

16 Jan 2026
LAST:

9.350

CHANGE:
 0.15		OPEN:
9.350		HIGH:
9.350		ASK:
0.000		VOLUME:
23
CHG(%):
1.63		PREV:
9.200		LOW:
9.350		BID:
0.000		 

CHART

RECENT END OF DAY PRICES

DateOpenHighLowCloseVolume
16 Jan 269.3509.3509.3509.35023
15 Jan 269.2009.2009.2009.20023
14 Jan 269.1009.1009.1009.10023
13 Jan 269.1009.1009.1009.10023
12 Jan 269.0009.0009.0009.00023
09 Jan 268.9008.9008.9008.90023
08 Jan 268.9008.9008.9008.90023
07 Jan 268.8008.8008.8008.80023
06 Jan 268.7508.7508.7508.75023
05 Jan 268.7008.7008.7008.70023

PROFILE

Name:Santen Pharmaceutical Co. Ltd
About:Santen Pharmaceutical Co., Ltd. engages in the research and development, manufacturing, and marketing of pharmaceuticals and medical devices in Japan, China, Asia, Europe, the Middle East, Africa, and internationally. Its product portfolio includes tafluprost/timolol maleate, a prostaglandin F2a derivative and a beta-adrenergic receptor blocker for the treatment of glaucoma and ocular hypertension; and ciclosporin, an ophthalmic emulsion for the treatment of vernal keratoconjunctivitis, as well as latanoprost, an ophthalmic emulsion of a prostaglandin F2a derivative filed for marketing approval for the treatment of glaucoma and ocular hypertension; and epinastine hydrochloride, a histamine H1 receptor antagonist filed for marketing approval for the treatment of allergic conjunctivitis. The company also offers netarsudil mesylate/latanoprost, a fixed dose combination drug of a ROCK inhibitor and a prostaglandin F2a derivative which is in phase III clinical trial for the treatment of glaucoma and ocular hypertension; and sepetaprost, a prostaglandin analogue eye drop drug that is in phase III clinical trials for the treatment of glaucoma and ocular hypertension. In addition, it develops oxymetazoline hydrochloride, a direct-acting alpha adrenergic receptor agonist which is in phase III clinical trial for treatment of ptosis; and omidenepag isopropyl, an EP2 receptor agonist that is in phase III clinical trial for the treatment of glaucoma and ocular hypertension. Further, the company offers atropine sulfate, a non-selective muscarinic antagonist that is in phase II/III clinical trials for the treatment of juvenile myopia; olodaterol hydrochloride, a ß2 receptor agonist that has completed phase 1/2a clinical trial for the treatment of a dry eye; and sirolimus, an ophthalmic suspension which is in phase 2a clinical trial for the treatment of fuchs endothelial corneal dystrophy and meibomian gland dysfunction. The company was founded in 1890 and is headquartered in Osaka, Japan.
Sector:Healthcare
Address:Grand Front Osaka Tower A, Osaka, Japan, 530-8552
Website:https://www.santen.com/en
ISIN:JP3336000009
LEI:529900TPT3I7C17MIM03

API SERVICE  NEW

Have you tried our new API Service yet?

For more information, visit our API page.

You can get your ApiKey over HERE.

If you're ready to get going, then jump over to:
https://api.eoddata.com

SYMBOL HISTORY

   Add to Watchlist

DOWNLOAD DATA

Download stock quote history quickly and easily in a variety of formats to suit your needs.

  Download

FUNDAMENTALS

Trailing P/E:17.50 
Forward P/E:11.36 
PEG Ratio:-0.59 
Price to Sales:0.01 
Price to Book:1.90 
Profit Margin:0.11 
Operating Margin:0.15 
Return on Assets:0.07 
Return on Equity:0.11 
DivYield:0.03 
Div/Share:36.00 
Revenue:1.581B 
EBITDA:320.15M 
Shares:332.65M 
Market Cap:3.11B 

TECHNICAL INDICATORS

MA5:9.152.2%
MA10:8.984.1%
MA20:8.835.9%
MA50:8.648.2%
MA100:8.796.3%
MA200:9.013.8%
STO9:100.00 
STO14:100.00 
RSI14:85.00 
MTM14:0.60
ROC14:0.07 
ATR:0.07 
Week High:9.350.0%
Week Low:8.905.1%
Month High:9.350.0%
Month Low:8.603.8%
Year High:10.229.3%
Year Low:7.9317.9%
Volatility:1.85 

RECENT SPLITS

Date Ratio
27 Mar 20155-1

RECENT DIVIDENDS

Date Amount
29 Sep 2025$0.11
28 Mar 2025$0.11
27 Sep 2024$0.10
28 Mar 2024$0.10
28 Sep 2023$0.09
30 Mar 2023$0.09
29 Sep 2022$0.09
30 Mar 2022$0.09
29 Sep 2021$0.09
30 Mar 2021$0.08